SCHEMBL12433863

SCHEMBL12433863

Fc1cccc(-c2ccnn2-c2c(Cl)ccc3c2CCNCC3)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 5/20 0.45
KDM5A P29375 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
HTR2C P28335 6/20 0.40
HTR2B P41595 6/20 0.40
HTR2A P28223 5/20 0.40
PARP10 Q53GL7 1/20 0.36
PARP11 Q9NR21 1/20 0.36
NISCH Q9Y2I1 1/20 0.34
PNMT P11086 3/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
HTR6 P50406 1/20 0.34
NR3C2 P08235 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL2209304 0.92 KDM5A (0.44) HTR7KDM5AKDM4CKDM5BHTR2C
SCHEMBL12433864 0.88 HTR2A (0.43) HTR7KDM5AKDM4CKDM5BHTR2C
SCHEMBL12433823 0.88 HTR2A (0.44) HTR7HTR2CHTR2BHTR2APNMT
SCHEMBL12433844 0.86 ASIC3 (0.46) HTR2CHTR2BHTR2APARP10PARP11
SCHEMBL12433828 0.84 CD274 (0.41) HTR7HTR2CHTR2BHTR2ANISCH
SCHEMBL12433855 0.83 HTR2A (0.41) HTR2CHTR2BHTR2APARP10PARP11
SCHEMBL12433853 0.83 HTR2A (0.44) HTR7HTR2CHTR2BHTR2APNMT
SCHEMBL12433852 0.80 HTR2C (0.40) HTR2CHTR2BHTR2ANISCHPNMT
Succinic Acid SCHEMBL2209062 0.80 HTR2B (0.38) HTR7KDM5AKDM4CKDM5BHTR2C
SCHEMBL12433862 0.80 HTR2A (0.42) KDM5AKDM4CKDM5BHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981882-B2 e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder ELI LILLY AND COMPANY (US) 2011-07-19 US disclosed
US-7981882-B2 e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder ELI LILLY AND COMPANY (US) 2011-07-19 US disclosed
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists ELI LILLY AND COMPANY 2008-09-04 US disclosed
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists ELI LILLY AND COMPANY 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists HTR2C, HTR3B, HTR1A HTR7 13/4885KDM5A 1016/4885KDM4C 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.